Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,798 Mln
P/E Ratio
24.41
P/B Ratio
1.74
Industry P/E
--
Debt to Equity
0.03
ROE
0.08 %
ROCE
7.27 %
Div. Yield
0 %
Book Value
18.51
EPS
1.32
CFO
$986.86 Mln
EBITDA
$1,107.79 Mln
Net Profit
$648.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Supernus Pharmaceuticals (SUPN)
| -10.90 | -1.47 | -16.42 | 6.48 | 3.01 | 11.20 | 8.88 |
|
BSE Sensex*
| 2.49 | 3.34 | 6.41 | 8.77 | 12.17 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Supernus Pharmaceuticals (SUPN)
| 24.72 | -18.87 | 22.33 | 15.90 | 6.07 | -28.60 | -16.55 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment... of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. Read more
Founder, President, CEO, Secretary & Director
Mr. Jack A. Khattar
Founder, President, CEO, Secretary & Director
Mr. Jack A. Khattar M.B.A.
Headquarters
Rockville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Supernus Pharmaceuticals Inc (SUPN) stood at $ 1,368 Mln as on 31-Dec-24
The share price of Supernus Pharmaceuticals Inc (SUPN) is $32.22 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Supernus Pharmaceuticals Inc (SUPN) has given a return of 3.01% in the last 3 years.
Supernus Pharmaceuticals Inc (SUPN) has a market capitalisation of $ 1,798 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Supernus Pharmaceuticals Inc (SUPN) is 24.41 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Supernus Pharmaceuticals Inc (SUPN) and enter the required number of quantities and click on buy to purchase the shares of Supernus Pharmaceuticals Inc (SUPN).
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
The CEO & director of Mr. Jack A. Khattar. is Supernus Pharmaceuticals Inc (SUPN), and CFO & Sr. VP is Mr. Jack A. Khattar M.B.A..
There is no promoter pledging in Supernus Pharmaceuticals Inc (SUPN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Supernus Pharmaceuticals Inc. (SUPN) | Ratios |
|---|---|
|
Return on equity(%)
|
7.55
|
|
Operating margin(%)
|
14.79
|
|
Net Margin(%)
|
11.16
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Supernus Pharmaceuticals Inc (SUPN) was $0 Mln.
$0.87
(
